• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'' by Gao and Qin.

作者信息

Tektonidou Maria G, Tincani Angela, Ward Michael M

机构信息

First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

出版信息

Ann Rheum Dis. 2023 May;82(5):e107. doi: 10.1136/annrheumdis-2021-220116. Epub 2021 Feb 23.

DOI:10.1136/annrheumdis-2021-220116
PMID:33622693
Abstract
摘要

相似文献

1
Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'' by Gao and Qin.对高和秦所著《关于〈欧洲抗风湿病联盟成人抗磷脂综合征管理建议〉的通信》的回复
Ann Rheum Dis. 2023 May;82(5):e107. doi: 10.1136/annrheumdis-2021-220116. Epub 2021 Feb 23.
2
Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults' by Zhou .
Ann Rheum Dis. 2022 Dec;81(12):e249. doi: 10.1136/annrheumdis-2020-219048. Epub 2020 Oct 1.
3
Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'.关于“欧洲抗风湿病联盟（EULAR）成人抗磷脂综合征管理建议”的通信
Ann Rheum Dis. 2023 May;82(5):e106. doi: 10.1136/annrheumdis-2021-220092. Epub 2021 Feb 23.
4
Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.对达莫索和范·贝尔斯就《美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准》的通信的回复。
Ann Rheum Dis. 2024 Feb 15;83(3):e7. doi: 10.1136/ard-2023-225074.
5
Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'.
Ann Rheum Dis. 2022 Dec;81(12):e248. doi: 10.1136/annrheumdis-2020-218950. Epub 2020 Oct 1.
6
Response to: Correspondence on 'Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients' by Liu.
Ann Rheum Dis. 2023 Aug;82(8):e180. doi: 10.1136/annrheumdis-2021-221780. Epub 2021 Nov 22.
7
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.EULAR 建议：风湿和肌肉骨骼疾病（包括红斑狼疮和抗磷脂综合征）的心血管风险管理。
Ann Rheum Dis. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2.
8
Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".关于“美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准”的通信
Ann Rheum Dis. 2024 Feb 15;83(3):e6. doi: 10.1136/ard-2023-225067.
9
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome.抗磷脂自身抗体消失后的复发性血栓形成事件：一项针对抗磷脂综合征患者的长期纵向研究。
Thromb Res. 2023 Apr;224:1-3. doi: 10.1016/j.thromres.2023.02.005. Epub 2023 Feb 10.
10
[Libman-Sacks endocarditis under apixaban in a patient with a high-risk profile venous antiphospholipid syndrome].[阿哌沙班治疗下的高危型静脉抗磷脂综合征患者的Libman-Sacks心内膜炎]
Rev Med Interne. 2021 Mar;42(3):218-222. doi: 10.1016/j.revmed.2020.08.009. Epub 2020 Nov 3.

引用本文的文献

1
Forecasting the Future of Antiphospholipid Syndrome: Prospects and Challenges.预测抗磷脂综合征的未来：前景与挑战。
Mo Med. 2023 Sep-Oct;120(5):359-366.
2
Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.羟氯喹在疾病中的生物学功能：从新冠病毒疾病到癌症
Pharmaceutics. 2022 Nov 22;14(12):2551. doi: 10.3390/pharmaceutics14122551.